5-Amino-1MQ vs GLP-3 RTA
5-Amino-1MQ and GLP-3 RTA are both studied in weight research, but they are different classes of compound with different reported research applications.
✓ both US-made · third-party tested · batch COA on every order
Last updated August 25, 2026
How do 5-Amino-1MQ and GLP-3 RTA differ?
5-Amino-1MQ (Small-molecule enzyme inhibitor (not a peptide)) is catalogued under weight & metabolic research; GLP-3 RTA (Synthetic triple-agonist peptide) is catalogued under weight & metabolic research. Verve lists 5 reported research applications for 5-Amino-1MQ and 5 for GLP-3 RTA. Both are made in the United States, screened by HPLC to a 99%+ purity standard, and shipped with a batch-level certificate of analysis.
| field | 5-Amino-1MQ | GLP-3 RTA |
|---|---|---|
| compound class | Small-molecule enzyme inhibitor (not a peptide) | Synthetic triple-agonist peptide |
| research area | weight & metabolic | weight & metabolic |
| reported research applications | 5 listed | 5 listed |
| supplied as | single compound | single compound |
| catalog sizes | 10mg | 10mg · 20mg · 30mg |
| purity standard | 99%+ by HPLC | 99%+ by HPLC |
| manufactured | United States | United States |
| batch COA | published per lot | published per lot |
| endotoxin-tested option | not offered | available |
| co-formulated together in | not co-formulated | not co-formulated |
| price from | $114.49 | $142.99 |
| availability | in stock | in stock |
Prices and stock read live from the catalog. Both compounds are supplied strictly as reference materials for in-vitro laboratory research.
What is 5-Amino-1MQ and what is GLP-3 RTA?
5-Amino-1MQ is classified as Small-molecule enzyme inhibitor (not a peptide); GLP-3 RTA as Synthetic triple-agonist peptide. Both profiles below cover scientific identity only — what the molecule is and which laboratory models it appears in. Verve supplies both strictly as in-vitro reference materials, and neither profile describes human or veterinary use.
5-Amino-1MQ
Small-molecule enzyme inhibitor (not a peptide)
5-Amino-1MQ is a small molecule rather than a peptide: a methylquinolinium compound that acts as a selective inhibitor of nicotinamide N-methyltransferase (NNMT). It is cell-permeable and carries a permanent positive charge on its quaternary nitrogen, a structural feature that shapes how it distributes in cellular assays and why it is used as a tool compound in enzyme-inhibition research.
full 5-Amino-1MQ profile →GLP-3 RTA
Synthetic triple-agonist peptide
GLP-3 RTA is a synthetic single-chain peptide engineered to act at three related class B G-protein-coupled receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its backbone is derived from the incretin peptide family and carries a fatty-acid modification that extends plasma half-life in pre-clinical systems, making it a widely cited reference agonist in incretin-receptor research.
full GLP-3 RTA profile →Which research models is each compound studied in?
5-Amino-1MQ and GLP-3 RTA both sit inside weight & metabolic research, so their listed models share framing while differing in specifics. The table lists 5 reported research applications for 5-Amino-1MQ and 5 for GLP-3 RTA. Rows are per compound, not equivalences.
| 5-Amino-1MQ — reported research applications | GLP-3 RTA — reported research applications |
|---|---|
| NNMT enzyme-inhibition and kinetics research | GLP-1, GIP, and glucagon receptor agonism research |
| NAD+ salvage-pathway and nicotinamide-metabolism studies | cAMP and class B GPCR signaling research models |
| S-adenosylmethionine and methyl-donor balance research | Comparative single-, dual-, and triple-agonist pharmacology studies |
| Adipocyte and cellular energy-metabolism research models | Metabolic-pathway and nutrient-handling research models |
| Small-molecule structure–activity and selectivity studies | Peptide half-life, lipidation, and stability research |
Research contexts only. Both compounds are supplied for laboratory research use only, and no entry above describes an effect in humans or animals.
What sizes and prices does verve list for 5-Amino-1MQ and GLP-3 RTA?
5-Amino-1MQ is listed from $114.49 and GLP-3 RTA from $142.99. The table below is every catalog size verve currently lists for the two compounds, at single-vial prices before the automatic multi-compound discount. Sizes describe the vial format supplied to the laboratory, nothing more.
| compound | size listed | price | availability |
|---|---|---|---|
| 5-Amino-1MQ | 10mg | $114.49 | in stock |
| GLP-3 RTA | 10mg | $142.99 | in stock |
| GLP-3 RTA | 20mg | $242.99 | in stock |
| GLP-3 RTA | 30mg | $328.99 | in stock |
Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.
shop the compounds →Frequently asked questions about 5-Amino-1MQ and GLP-3 RTA
What is 5-Amino-1MQ?
5-Amino-1MQ is a small molecule, not a peptide — a methylquinolinium compound that selectively inhibits the enzyme nicotinamide N-methyltransferase (NNMT). Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
Is 5-Amino-1MQ a peptide?
No. It is a small-molecule enzyme inhibitor with no amino-acid backbone, which is why it is handled and stored differently from the peptides in the catalog. It is supplied strictly for laboratory research.
What is GLP-3 RTA?
GLP-3 RTA is a synthetic peptide that acts as an agonist at three receptors — GLP-1, GIP, and glucagon. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is GLP-3 RTA studied for in research?
In in-vitro and pre-clinical models it is used as a reference agonist in incretin-receptor pharmacology, cAMP signaling, and metabolic-pathway research. Verve makes no claims about use in humans or animals.
related comparisons
verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.